Endocrinology

This episode highlights the recent technological advancements made by Medtronic Diabetes in treating type 1 and 2 diabetes.

Explore key FDA decisions in Q4 2025, impacting treatments for atopic dermatitis, chronic rhinosinusitis, and rare diseases.

The resubmission is based on results from 5 randomized clinical trials in the ONWARDS type 2 diabetes phase 3a program.

The approval of the selectively targeted somatostatin receptor type 2 agonist is supported by data from the phase 3 PATHFNDR-1 and PATHFNDR-2 trials.

Biolinq Shine aims to provide continuous glucose monitoring, as well as sleep and activity data, without requiring injections.

This episode highlights the results of the ATTAIN-1 and STEP UP clinical trials, examining the potential of their respective GLP-1 RA subjects.

A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.

Investigators formulated a series of hypothetical situations to test the overall economic impact of introducing lonapegsomatropin into the growth hormone market.

The investigational oral GLP-1 RA showed superiority in glycemic control and weight loss among patients with uncontrolled T2D.

Tirzepatide saw improvements in A1C and body mass index, which were maintained over the 30-week trial and into the 52-week extension study.

New research from Stockholm, Sweden, has shown the correlation between smoking and insulin sensitivity, with genetic susceptibility increasing the risk further.

Pediatric patients with type 1 diabetes often have severely limited access to care, allowing very few to achieve HbA1c goals.

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

A technology review from the University of Virginia analyzes the successes of AID devices, as well as indicating where the technology still has to go.

Lexicon aims to address concerns from a 2024 complete response letter, which cited an increased risk of diabetic ketoacidosis.

Cadisegliatin, a potential first-in-class oral treatment for type 1 diabetes, has been granted Breakthrough Designation by the FDA.

Explore the latest advancements in diabetes technology, including FDA-approved insulin pumps and innovative CGMs for weight management.

Hosts explore the latest findings on GLP-1 medications, semaglutide and tirzepatide, from ESC Congress 2025.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.

Ionis Therapeutics, Inc. also announced plans to submit an sNDA for olezarsen based on these trial results by the end of 2025.

Stay updated with the latest healthcare breakthroughs, including FDA news, vaccine guidelines, and orforglipron data, in this week's essential news roundup.

Recent research has shown a reduction of nearly 1/3 in type 2 diabetes risk associated with adherence to a Mediterranean diet, calorie reduction, and moderate exercise.

Perceived changes in glucose metabolism and regulation in turn lead to more severe reported menopausal symptoms.

Orforglipron met the primary and all key secondary endpoints in patients with obesity/overweight and type 2 diabetes, supporting global regulatory submissions.